Pall Corporation And Gambro BCT Sign Global Supply Agreement For Leukoreduction Filters
EAST HILLS, N.Y.--(BUSINESS WIRE)--March 10, 2005--Pall Corporation (NYSE:PLL) today announced that it has signed a new multi-year contract for leukocyte (white blood cell) reduction filters with Gambro BCT, Inc. Pall will be the sole source, global provider of leukoreduction filters for red cells, plasma and platelets for Gambro BCT's automated blood collection and whole blood processing systems.